HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 87.97% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Trading Down 2.8 %

Shares of NASDAQ DNTH opened at $21.28 on Wednesday. The company has a market capitalization of $629.82 million, a P/E ratio of -8.51 and a beta of 1.82. Dianthus Therapeutics has a 12 month low of $18.13 and a 12 month high of $33.77. The stock has a 50 day moving average of $22.65 and a 200-day moving average of $24.94.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently made changes to their positions in DNTH. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at $26,000. Quest Partners LLC raised its stake in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the fourth quarter worth about $33,000. KBC Group NV acquired a new stake in Dianthus Therapeutics during the fourth quarter worth about $35,000. Finally, BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics in the 4th quarter valued at about $59,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.